Dexmedetomidine
A highly selective alpha-2 adrenergic agonist used intravenously for sedation and analgesia in intensive care unit patients and as a procedural sedative, with the unique property of producing sedation without respiratory depression. It also has analgesic properties and reduces opioid requirements.
Masse moléculaire
200,2800 g/mol
LogP
3,10
TPSA
28,70 Ų
Règle des 5 de Lipinski
Conforme
Aires thérapeutiques
Mécanisme d'action
Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …
Structure 2D
Cite this structure
Embed this structure
SMILES
Cc1cccc([C@H](C)c2c[nH]cn2)c1C
InChI
InChI=1S/C13H16N2/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13/h4-8,11H,1-3H3,(H,14,15)/t11-/m0/s1
Molecular Formula
C13H16N2
HBD / HBA
1 / 1
Liaisons Rotatives
2
Atomes Lourds
15
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
A highly selective alpha-2 adrenergic agonist used intravenously for sedation and analgesia in intensive care unit patients and as a procedural sedative, with the unique property of producing sedation without respiratory depression. It also has analgesic properties and reduces opioid requirements.
Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.
Yes, Dexmedetomidine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL778. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5311068. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="dexmedetomidine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/dexmedetomidine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/dexmedetomidine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/dexmedetomidine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="dexmedetomidine"></drugfyi-drug>